Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy

Immunotherapies have shown modest benefits in the current clinical trials for ovarian cancer. The tumor microenvironment (TME) in an immunosuppressive phenotype contributes to this “failure” of immunotherapy in ovarian cancer. Many stromal cell types in the TME (e.g., tumor-associated macrophages an...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Hongling, He, Xiang, Wang, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670735/
https://www.ncbi.nlm.nih.gov/pubmed/36405688
http://dx.doi.org/10.3389/fimmu.2022.1035997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670735/
https://www.ncbi.nlm.nih.gov/pubmed/36405688
http://dx.doi.org/10.3389/fimmu.2022.1035997

Ejemplares similares